UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: September 20, 2017
(Date of earliest event reported)
CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware |
1-36598 |
04-3321804 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
3301 Agriculture Drive
Madison, WI 53716
(Address of principal executive offices)
(608) 441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 7.01 | REGULATION FD DISCLOSURE |
On September 20, 2017, we issued a press release announcing that the company will present and meet with investors at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26 at 9:30 AM ET. The conference will be held at the Sofitel New York in New York City. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
Number | Title | |
99.1 | Press release dated September 20, 2017, titled “Cellectar Biosciences to Present at the Ladenburg Thalmann Healthcare Conference” | |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 20, 2017 | CELLECTAR BIOSCIENCES, INC. | ||
By: | /s/ John P. Hamill | ||
Name: John P. Hamill | |||
Title: Interim Chief Financial Officer |
3 |
Exhibit 99.1
Cellectar Biosciences to Present at the
Ladenburg Thalmann 2017 Healthcare Conference
Madison, Wis., (September 20, 2017) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), an oncology-focused biotechnology company (the “company”), today announced that president and CEO Jim Caruso will present and meet with investors at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26th at 9:30 AM ET in the St. Germain Room of the Sofitel New York in New York City.
The live presentation will be webcast at http://wsw.com/webcast/ladenburg3/clrb,
and archived on the company’s website following
the conference.
About Cellectar Biosciences, Inc.
Cellectar Biosciences (Nasdaq: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery
of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in
a broad range of cancers, even sites of metastases. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic
radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a
Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy
in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and
has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and
collaborative R&D efforts. For more information please visit www.cellectar.com.
# # #
Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com